Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|February 12, 2021
Experience the Art of Science on Your Drug Development Project with Pfizer CentreOne®
Author(s)Pfizer CentreOne
Pfizer CentreOne® is a global CDMO embedded within Pfizer and a leading supplier of specialty APIs. Visit www.pfizercentreone.com.
Pfizer CentreOne has years of drug development experience and there are few challenges we haven’t faced. We leverage our development and tech transfer expertise to guide your product through milestones and overcome project challenges to take you further.
Worldwide, our sites have been developing and manufacturing Pfizer’s broad array of innovative molecules for decades, and this legacy helps ensure a successful collaboration with you:
- Over 90 new products in
Pfizer's drug development pipeline - More than 400 tech transfers in various stages a year (2019)
- Regulatory experience supporting 60+ countries
We offer the knowledge, network, and expert legacy to act as your creative problem solver and collaborative partner on your drug development project.
We offer an expert suite of development and optimization services in formulation, clinical drug manufacturing, analytical testing, validation, and method development.
Access our wide-range of capabilities to support today’s therapeutic trends:
- Small molecule APIs
- Large molecule biologics
- Oral solids
- Sterile injectables
Pfizer CentreOne
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5